The stock of Aphria Inc (CVE:APH) hit a new 52-week high and has $7.64 target or 74.00% above today’s $4.39 share price. The 9 months bullish chart indicates low risk for the $434.12M company. The 1-year high was reported on Nov, 10 by Barchart.com. If the $7.64 price target is reached, the company will be worth $321.25 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 1.58 million shares traded hands. Aphria Inc (CVE:APH) has risen 6.00% since October 11, 2016 and is uptrending. It has outperformed by 0.35% the S&P500.
More notable recent Aphria Inc (CVE:APH) news were published by: Seekingalpha.com which released: “The Most Compelling Marijuana Investment: Aphria” on June 01, 2016, also Midasletter.com with their article: “Aphria Inc. CEO Vic Neufeld on Canopy Growth, Organigram and Recreational …” published on November 10, 2015, Seekingalpha.com published: “Aphria: A Growing Green Gem” on August 22, 2016. More interesting news about Aphria Inc (CVE:APH) were released by: Marketwired.com and their article: “Aphria Inc. Announces $25 Million Bought Deal” published on July 28, 2016 as well as Midasletter.com‘s news article titled: “TSX Best Marijuana Bets in 2016: Canopy Growth Corp, Aphria Inc, and …” with publication date: January 02, 2016.
Aphria Inc., formerly Black Sparrow Capital Corp., is a Canada company, which is engaged in producing and selling medical marijuana through retail sales and wholesale channels. The company has a market cap of $434.12 million. The Company’s retail sales are primarily sold through the Company’s online store, as well as telephone orders. It has a 181.63 P/E ratio. The Company’s wholesale shipments are sold to other Medical Purposes Regulations Licensed Producers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.